guidelinesbone healthbone‐modifying drugsBone health management for breast cancer spans the entire cycle of patient care, including the prevention and treatment of bone loss caused by early breast cancer treatment, the adjuvant application of bone‐modifying agents to improve prognosis, and the ...
NCCN Guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicans and payors
It has been documented that variations exist in breast cancer treatment despite wide dissemination of clinical practice guidelines. The aim of this population-based study was to evaluate the impact of regional guidelines (Piedmont guidelines, PGL) for br
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a p
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated treatment known as hypofr
The aim of this population-based study was to evaluate the impact of regional guidelines (Piedmont guidelines, PGL) for breast cancer diagnosis and treatment on quality-of-care indicators in the Northwestern Italian region of Piedmont. Methods We included two samples of women aged 50–69 years...
, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer....
through literature research and expert discussion and evaluated the relevant evidence with reference to the grading of recommendations assessment,development,and evaluation.The CSBrS formulated the clinical practice guidelines to provide a reference for physicians specializing in breast cancer and other fields...
The full NCCN Guidelines for Breast Cancer are avail- able at NCCN. The primary goals of systemic treat- ment of recurrent/stage IV breast cancer are palliating symptoms, prolonging survival, and maintaining or improving quality of life. Hormone receptor (HR) status, ...
(P-gp), the multidrug resistance associated protein (MRP1), the lung resistance protein (LRP), and, more recently, the breast cancer resistance protein... B Tan,D Piwnica-Worms,L Ratner - 《Current Opinion in Oncology》 被引量: 881发表: 2000年 The era of molecular and other non-culture...